<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>13-ACITRETIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACITRETIN" rxcui="16818">
<ATC code="D05BB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ALCOHOL (DRINK OR INGREDIENT)" >
</DRUG>
</DRUG2>
<DESCRIPTION>With women of child bearing age, risk of transformation of the acitretin into etretinate, a powerful agent of birth defects and malformations with a very prolonged half life (120 days), exposing the woman to a major risk of these birth defects and malformations of the child in case of pregnancy, during the treatment and two months after it ends. </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>13-ACITRETIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACITRETIN" rxcui="16818">
<ATC code="D05BB02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METHOTREXATE" rxcui="6851">
<ATC code="L04AX03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the hepatotoxicity of the methotrexate </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these substances together is judged necessary, strengthen liver function testing. </COMMENT>
</INTERACTION>
</INTERACTIONS>
